Answers are grounded in this paper and cite their sources.
The treatment of tuberculosis, despite the intensification of research into new drugs, remains a current problem of phthisiopulmonology due to the emergence of mycobacteria with multiple and extensive resistance, decreased patient adherence to treatment due to long duration of treatment and side effects, transformation of mycobacteria into latent metabolic forms. Elucidation of new compounds influencing metabolism and energy processes opens new perspectives to optimize the treatment of TB-MDR and TB-XDR, as well as the development of new therapeutic regimens that would shorten the duration of treatment by reducing the incidence of adverse reactions and increasing patient compliance
No takes yet. Share an insight, caveat, or question.
Bacinschi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: